Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

Data presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH) "Because follicular lymphoma is incurable, patients with relapsed or refractory follicular ...

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term ...

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse ...

Please provide your email address to receive an email when new articles are posted on . 61% of patients with heavily pretreated CLL responded to single-agent epcoritamab therapy. Researchers intend to ...

The US Food and Drug Administration approved epcoritamab (Epkinly, AbbVie and GenMab) today for adults with relapsed/refractory diffuse large B-cell lymphoma following at least two lines of systemic ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to epcoritamab for treatment of certain patients with advanced lymphoma, ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps The global study enrolled 483 patients with R/R DLBCL with at least ...

“Today’s milestone marks meaningful progress for people living with follicular lymphoma. With a bispecific-based therapy that can be administered in a variety of medical settings, patients have the ...